• 1
    Stuart MJ, Setty BNY. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 2001; 20: 2746.
  • 2
    Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 421623.
  • 3
    Mohan JS, Lip GY, Wright J, Bareford D, Blann AD. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and inflammation. Blood Coagul Fibrinolysis 2005; 16: 20914.
  • 4
    Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998;101:1899904.
  • 5
    Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102: 267883.
  • 6
    Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 18.
  • 7
    Camerer E, Kolstø A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 141.
  • 8
    Mazzolai L, Silacci P, Bouzourene K, Daniel F, Brunner H, Hayoz D. Tissue factor activity is upregulated in human endothelial cells exposed to oscillatory shear stress. Thromb Haemost 2002; 87: 10628.
  • 9
    Solovey A, Kollander R, Shet A, Milbauer LC, Choong S, Panoskaltsis-Mortari A, Blazar BR, Kelm RJ Jr, Hebbel RP. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104: 8406.
  • 10
    Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO III, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 13839.
  • 11
    Minneci PC, Deans KJ, Zhi H, Yuen PST, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT, Solomon SB. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest 2005; 115: 340917.
  • 12
    Kato GJ, McGowan V, Machado RF, Little JA, Taylor J VI, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood 2006; 107: 227985.
  • 13
    Wagener FA, Feldman E, DeWitte T, Abraham NG. Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med 1997; 216: 45663.
  • 14
    Setty BNY, Gayen-Betal S. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood 2008; 111:90514.
  • 15
    Wahl C, Liptay S, Guido A, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 116374.
  • 16
    Pendurthi UR, Williams JT, Rao LVM. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1 and NFκB. Arterioscler Thromb Vasc Biol 1997; 17: 340613.
  • 17
    Mackman N. Regulation of the tissue factor gene. FASEB J 1995; 9: 8839.
  • 18
    Arruda MA, Rossi AG, DeFreitas MS, Barja-Fidalgo C, Graca-Souza AV. Heme inhibits human neutrophil apoptosis: involvement of phosphoinositide-3-kinase, MAPK, and NF-κB. J Immunol 2004; 173: 202330.
  • 19
    Hasan RN, Schafer AI. Hemin upregulates Egr-1 expression in vascular smooth muscle cells via reactive oxygen species ERK-1/2–Elk-1 and NF-κB. Circ Res 2008; 18: 4250.
  • 20
    Hartmann RC, Jenkins DE, McKee L. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy. Medicine 1966; 45: 33163.
  • 21
    DeLatour RP, Mary J-Y, Slanoubat C, Terriou L, Etienne G, Mohty M, Roth S, DeGuibert S, Cahn J-Y, Socie G. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 118: 1072A.
  • 22
    Davis CL, Kausz AT, Zager RA, Kharasch ED, Cochran RP. Acute renal failure after cardiopulmonary bypass is related to decreased serum ferritin levels. J Am Soc Nephrol 1999; 10: 2396402.
  • 23
    Fei H, Berliner JA, Parhami F, Drake TA. Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb 1993; 13: 171117.
  • 24
    Roth RI. Hemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin. Blood 1994; 83: 28605.
  • 25
    Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle cell disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007; 110: 216672.
  • 26
    Styles L, DeJong K, Vichinsky E, Lubin B, Adams R, Kuypers F. Increased RBC phosphatidylserine exposure in sickle cell disease patients at risk for stroke by transcranial Doppler screening. Blood 1997; 90: 604a.
  • 27
    Porto BN, Alves LS, Fernandez PL, Dutra TP, Figueiredo RT, Graca-Souza AV, Bozza MT. Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J Biol Chem 2007; 282: 202219.
  • 28
    Graca-Souza AV, Arruda MAB, DeFreitas MS, Barja-Fidalgo C, Oliveira PL. Neutrophil activation by heme: implications for inflammatory processes. Blood 2002; 99: 41605.